Jeremey Chien

List of Publications by Year
in descending order

131 papers	13,952 citations	70961 41 h-index	29081 104 g-index
141 all docs	141 docs citations	141 times ranked	22381 citing authors

#	Article	IF	Citations
1	Synchronous Basal Cell Carcinoma and Squamous Cell Carcinoma of Nasal Vestibule With Novel Unique Variants Identified by Whole-exome Sequencing. In Vivo, 2022, 36, 251-257.	0.6	2
2	Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior. Cells, 2022, 11, 1403.	1.8	15
3	Multiple Components of Protein Homeostasis Pathway Can Be Targeted to Produce Drug Synergies with VCP Inhibitors in Ovarian Cancer. Cancers, 2022, 14, 2949.	1.7	3
4	Effect of the p53 P72R Polymorphism on MutantTP53Allele Selection in Human Cancer. Journal of the National Cancer Institute, 2021, 113, 1246-1257.	3.0	16
5	Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 1666-1681.	3.0	61
6	Quinacrine Induces Nucleolar Stress in Treatment-Refractory Ovarian Cancer Cell Lines. Cancers, 2021, 13, 4645.	1.7	7
7	Quinacrine Has Preferential Anticancer Effects on Mesothelioma Cells With Inactivating NF2 Mutations. Frontiers in Pharmacology, 2021, 12, 750352.	1.6	4
8	MutEx: a multifaceted gateway for exploring integrative pan-cancer genomic data. Briefings in Bioinformatics, 2020, 21, 1479-1486.	3.2	12
9	The P72R Polymorphism in R248Q/W p53 Mutants Modifies the Mutant Effect on Epithelial to Mesenchymal Transition Phenotype and Cell Invasion via CXCL1 Expression. International Journal of Molecular Sciences, 2020, 21, 8025.	1.8	4
10	In vivoÂmodeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genetics, 2020, 16, e1008808.	1.5	27
11	Short-term Organoid Culture For Drug Sensitivity Testing in High Grade Serous Ovarian Cancer. Gynecologic Oncology, 2020, 156, e27.	0.6	1
12	Pan-cancer analysis of whole genomes. Nature, 2020, 578, 82-93.	13.7	1,966
13	Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. Gynecologic Oncology, 2020, 157, 783-792.	0.6	46
14	A large-scale comparative study of isoform expressions measured on four platforms. BMC Genomics, 2020, 21, 272.	1.2	8
15	Heterozygous mutations in valosin-containing protein (VCP) and resistance to VCP inhibitors. Scientific Reports, 2019, 9, 11002.	1.6	5
16	Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer. Frontiers in Oncology, 2019, 9, 986.	1.3	7
17	Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity. Communications Biology, 2019, 2, 335.	2.0	35
18	Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. International Journal of Cancer, 2019, 144, 178-189.	2.3	103

#	Article	IF	Citations
19	Abstract AP13: GENOME-SCALE CRISPR KNOCKOUT SCREEN IDENTIFIES TIGAR AS A MODIFIER OF PARP INHIBITOR SENSITIVITY. , 2019, , .		0
20	Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer. Scientific Reports, 2018, 8, 2487.	1.6	51
21	VaDiR: an integrated approach to Variant Detection in RNA. GigaScience, 2018, 7, .	3.3	16
22	Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition. Molecular Cancer Research, 2018, 16, 961-973.	1.5	32
23	Emerging Cancer Therapeutic Targets in Protein Homeostasis. AAPS Journal, 2018, 20, 94.	2.2	28
24	Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer. Frontiers in Oncology, 2018, 8, 58.	1.3	7
25	Co-selected mutations in VCP: a novel mechanism of resistance to VCP inhibitors. Cell Death and Disease, 2018, 9, 35.	2.7	6
26	Abstract 2448: Chemotherapy drug-induced AXL activation and cell survival signaling via reactive oxygen species that can be inhibited to enhance drug efficacy in mesothelioma. , 2018, , .		0
27	Abstract A51: FOXM1 inhibition by thiostrepton synergizes with olaparib by attenuating adaptive response in ovarian cancer cells. , 2018, , .		0
28	Abstract A40: Specific mutations in the D1-D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors. , 2018, , .		0
29	Abstract B41: Studying the effect of germline polymorphisms on somatic hotspot mutations in TP53 for the treatment of high-grade serous ovarian carcinoma. , 2018, , .		0
30	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. Clinical Cancer Research, 2017, 23, 3794-3801.	3.2	103
31	Network-based machine learning and graph theory algorithms for precision oncology. Npj Precision Oncology, 2017, 1, 25.	2.3	74
32	Complete Transcriptome RNA-Seq. Methods in Molecular Biology, 2017, 1513, 141-162.	0.4	2
33	The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer. Oncogene, 2017, 36, 2565-2576.	2.6	48
34	Specific mutations in the D1â€“D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors. Cell Death Discovery, 2017, 3, 17065.	2.0	28
35	digitâ€”a tool fordetection andidentification ofgenomicinterchromosomaltranslocations. Nucleic Acids Research, 2017, 45, gkx010.	6.5	0
36	Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy. Frontiers in Pharmacology, 2017, 8, 970.	1.6	34

#	Article	IF	Citations
37	Mifepristone increases mRNA translation rate, triggers theÂunfolded protein response, increases autophagic flux, andÂkills ovarian cancer cells in combination with proteasomeÂor lysosome inhibitors. Molecular Oncology, 2016, 10, 1099-1117.	2.1	29
38	VCP inhibitors induce endoplasmic reticulum stress, causeÂcell cycle arrest, trigger caspaseâ€mediated cell deathÂand synergistically kill ovarian cancer cells in combination with Salubrinal. Molecular Oncology, 2016, 10, 1559-1574.	2.1	69
39	Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells. Journal of Biological Chemistry, 2016, 291, 18897-18914.	1.6	70
40	A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget, 2016, 7, 7381-7389.	0.8	7
41	The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget, 2016, 7, 27185-27198.	0.8	37
42	TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet?. Translational Cancer Research, 2016, 5, S264-S268.	0.4	10
43	Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway. Translational Cancer Research, 2016, 5, S514-S519.	0.4	8
44	Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. BMC Cancer, 2015, 15, 887.	1.1	30
45	Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Breast Cancer Research, 2015, 17, 128.	2.2	43
46	Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics. Oncotarget, 2015, 6, 25943-25961.	0.8	53
47	Network-Based Isoform Quantification with RNA-Seq Data for Cancer Transcriptome Analysis. PLoS Computational Biology, 2015, 11, e1004465.	1.5	17
48	Neonatal Progesterone Programs Adult Uterine Responses to Progesterone and Susceptibility to Uterine Dysfunction. Endocrinology, 2015, 156, 3791-3803.	1.4	10
49	Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples. Scientific Reports, 2015, 5, 12335.	1.6	54
50	TP53mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Research, 2015, 43, 6945-6958.	6.5	46
51	PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. European Journal of Cancer, 2015, 51, 879-892.	1.3	53
52	Molecular determinants of chemotherapy resistance in ovarian cancer. Pharmacogenomics, 2015, 16, 1763-1767.	0.6	5
53	Challenges and opportunities for next-generation sequencing in companion diagnostics. Expert Review of Molecular Diagnostics, 2015, 15, 193-209.	1.5	12
54	Abstract 1992: Evidence for modulation of FoxM1 by p21 in ovarian cancer. , 2015, , .		0

#	Article	IF	Citations
55	Abstract POSTER-TECH-1109: Robust gene expression and mutation analyses from RNA-sequencing of formalin-fixed diagnostic tumor samples. , 2015, , .		0
56	Abstract POSTER-THER-1409: Targeting p53-FoxM1 axis in ovarian cancer. , 2015, , .		0
57	Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. Oncotarget, 2014, 5, 11365-11380.	0.8	37
58	Tumor Hypomethylation at 6p21.3 Associates with Longer Time to Recurrence of High-Grade Serous Epithelial Ovarian Cancer. Cancer Research, 2014, 74, 3084-3091.	0.4	32
59	Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer. Cancer & Metabolism, 2014, 2, 13.	2.4	27
60	661: HtrA1 as a novel plasma biomarker for ectopic pregnancy. American Journal of Obstetrics and Gynecology, 2014, 210, S324.	0.7	0
61	Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. BMC Medical Genomics, 2014, 7, 8.	0.7	32
62	Expression of Protease HtrA1 Is Increased at the Site of Ectopic Pregnancy. Obstetrics and Gynecology, 2014, 123, 32S-33S.	1.2	1
63	Abstract 260: Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. , 2014, , .		2
64	Abstract 4281: Targeted or whole genome sequencing of formalin-fixed tissue samples. , 2014, , .		0
65	Metformin intake is associated with better survival in ovarian cancer. Cancer, 2013, 119, 555-562.	2.0	139
66	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. Cancer Research, 2013, 73, 7222-7231.	0.4	153
67	HtrA1 Peptidase. , 2013, , 2577-2584.		1
68	Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Human Molecular Genetics, 2013, 22, 3038-3047.	1.4	60
69	Network-based Survival Analysis Reveals Subnetwork Signatures for Predicting Outcomes of Ovarian Cancer Treatment. PLoS Computational Biology, 2013, 9, e1002975.	1.5	151
70	Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment. Frontiers in Oncology, 2013, 3, 251.	1.3	84
71	Metformin Intake Is Associated With Better Survival in Ovarian Cancer. Obstetrical and Gynecological Survey, 2013, 68, 293-294.	0.2	1
72	Assessment of Resistance to Anoikis in Ovarian Cancer. Methods in Molecular Biology, 2013, 1049, 347-354.	0.4	4

#	Article	IF	Citations
73	Abstract 2008: Genomic medicine using NexGen sequencing to personalized treatment of metastatic adenoid cystic carcinoma (ADCC).. , 2013, , .		0
74	Role of heparan sulfatases in ovarian and breast cancer. American Journal of Cancer Research, 2013, 3, 34-45.	1.4	22
75	768: Biomarkers of severe preeclampsia identified in urinary exosomes. American Journal of Obstetrics and Gynecology, 2012, 206, S339.	0.7	0
76	HtrA1 sensitizes ovarian cancer cells to cisplatinâ€induced cytotoxicity by targeting XIAP for degradation. International Journal of Cancer, 2012, 130, 1029-1035.	2.3	43
77	Highly Parallel Genome-Wide Expression Analysis of Single Mammalian Cells. PLoS ONE, 2012, 7, e30794.	1.1	24
78	Abstract 3272: Characterization of mouse oviductal glycoprotein (Ovgp1) promoter driven SV40 T large antigen: fallopian tube cancer and leiomyosarcoma mouse model. , 2012, , .		0
79	Abstract 5120: Functional genetic screens identify a rare isoform of RABL3 as a modulator of paclitaxel resistance in ovarian cancer. , 2012, , .		0
80	Abstract 3179: Targeted re-sequencing of cancer-related genes from matched FFPE and fresh-frozen tumor samples using the Illumina sequencing platform. , 2012, , .		0
81	Abstract 4960: The role of YY1 in paclitaxel-induced cytotoxicity in epithelial ovarian cancer. , 2012, , .		0
82	Expression and Functional Significance of HtrA1 Loss in Endometrial Cancer. Clinical Cancer Research, 2011, 17, 427-436.	3.2	39
83	Integrated genomic analyses of ovarian carcinoma. Nature, 2011, 474, 609-615.	13.7	6,541
84	Comparison of gene expression patterns between avian and human ovarian cancers. Gynecologic Oncology, 2011, 120, 256-264.	0.6	18
85	714: Invasive placentation: an investigation into the gene expression profile of pregnancies complicated by placenta previa, accreta, increta and percreta. American Journal of Obstetrics and Gynecology, 2011, 204, S281-S282.	0.7	0
86	FusionHunter: identifying fusion transcripts in cancer using paired-end RNA-seq. Bioinformatics, 2011, 27, 1708-1710.	1.8	73
87	Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1638-1648.	1.1	31
88	Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. Modern Pathology, 2011, 24, 277-287.	2.9	30
89	HSulf-1 Modulates FGF2- and Hypoxia-Mediated Migration and Invasion of Breast Cancer Cells. Cancer Research, 2011, 71, 2152-2161.	0.4	49
90	Abstract 1531: HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation. , 2011, , .		1

#	Article	IF	Citations
91	Abstract 4015: Flavopiridol-induced upregulation of HtrA1 is associated with suppression of its negative transcriptional regulator WT-1 and with enhanced chemosensitivity. , 2011, , .		1
92	TCEAL7, a putative tumor suppressor gene, negatively regulates NF-Î¹B pathway. Oncogene, 2010, 29, 1362-1373.	2.6	41
93	High Temperature Requirement A3 (HtrA3) Promotes Etoposide- and Cisplatin-induced Cytotoxicity in Lung Cancer Cell Lines. Journal of Biological Chemistry, 2010, 285, 12011-12027.	1.6	45
94	Downregulation of HtrA1 Promotes Resistance to Anoikis and Peritoneal Dissemination of Ovarian Cancer Cells. Cancer Research, 2010, 70, 3109-3118.	0.4	143
95	WT1 as a substrate of HtrA2: a potential pathway for therapeutic targeting by HtrA proteases. Future Oncology, 2010, 6, 1233-1235.	1.1	4
96	Abstract 3276: Characterization of tumors in mouse oviduct-specific glycoprotein 1(Ogp1) promoter-driven SV40 large T antigen. , 2010, , .		1
97	Abstract 3544: Assessment of chemo-response in cells derived from patients with malignant ascites. , 2010, , .		0
98	Serine Protease HtrA1 Associates with Microtubules and Inhibits Cell Migration. Molecular and Cellular Biology, 2009, 29, 4177-4187.	1.1	99
99	HtrA Serine Proteases as Potential Therapeutic Targets in Cancer. Current Cancer Drug Targets, 2009, 9, 451-468.	0.8	114
100	Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecologic Oncology, 2009, 114, 3-11.	0.6	57
101	Identification of tubulins as substrates of serine protease HtrA1 by mixtureâ€based oriented peptide library screening. Journal of Cellular Biochemistry, 2009, 107, 253-263.	1.2	36
102	Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. Journal of Clinical Investigation, 2009, 119, 1396-1396.	3.9	1
103	Elevated expression of serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion. American Journal of Obstetrics and Gynecology, 2008, 199, 557.e1-557.e10.	0.7	38
104	255: The degree of expression of serine protease HtrA1 and its affects on trophoblast cell invasion in normal and abnormal placentation. American Journal of Obstetrics and Gynecology, 2008, 199, S83.	0.7	0
105	A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. Oncogene, 2008, 27, 7223-7234.	2.6	38
106	784: Cytokines and hormonal regulation of HTRA1 expression in trophoblast cells. American Journal of Obstetrics and Gynecology, 2008, 199, S222.	0.7	0
107	816: Serum HtrA1 is a novel marker for early-onset severe preeclampsia. American Journal of Obstetrics and Gynecology, 2008, 199, S230.	0.7	0
108	The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics, 2008, 9, 1069-1077.	0.6	51

#	Article	IF	Citations
109	Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. Journal of Clinical Investigation, 2008, 118, 2908-16.	3.9	194
110	Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer. Journal of Biological Chemistry, 2007, 282, 14413-14420.	1.6	71
111	Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. Journal of Cellular Biochemistry, 2007, 102, 1117-1129.	1.2	45
112	Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene, 2007, 26, 4969-4978.	2.6	102
113	DIXDC1 isoform, l-DIXDC1, is a novel filamentous actin-binding protein. Biochemical and Biophysical Research Communications, 2006, 347, 22-30.	1.0	27
114	Human HtrA1 retards JEG-3 choriocarcinoma cytotrophoblast invasionÂin vitro. American Journal of Obstetrics and Gynecology, 2006, 195, S37.	0.7	0
115	HSulf-1 Inhibits Angiogenesis and Tumorigenesis In vivo. Cancer Research, 2006, 66, 6025-6032.	0.4	131
116	Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma. Clinical Cancer Research, 2006, 12, 6133-6143.	3.2	39
117	A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration. Science, 2006, 314, 992-993.	6.0	735
118	Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. Journal of Clinical Investigation, 2006, 116, 1994-2004.	3.9	130
119	Placental expression of HtrA1 in pregnancies complicated by preeclampsia. American Journal of Obstetrics and Gynecology, 2005, 193, S69.	0.7	0
120	Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene, 2005, 24, 5089-5100.	2.6	57
121	Heterozygous ATR Mutations in Mismatch Repairâ€“Deficient Cancer Cells Have Functional Significance. Cancer Research, 2005, 65, 7091-7095.	0.4	51
122	HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene, 2004, 23, 1439-1447.	2.6	132
123	A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene, 2004, 23, 1636-1644.	2.6	157
124	Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer. Journal of Biological Chemistry, 2003, 278, 23107-23117.	1.6	215
125	Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Research, 2002, 62, 262-70.	0.4	76
126	Calcitonin is a prostate epithelium-derived growth stimulatory peptide. Molecular and Cellular Endocrinology, 2001, 181, 69-79.	1.6	36

#	Article	IF	Citations
127	Role of stimulatory guanine nucleotide binding protein (Gs?) in proliferation of PC-3M prostate cancer cells. International Journal of Cancer, 2001, 91, 46-54.	2.3	27
128	Calcitonin is expressed in gonadotropes of the anterior pituitary gland: its possible role in paracrine regulation of lactotrope function. Journal of Endocrinology, 2001, 171, 217-228.	1.2	28
129	Constitutive activation of stimulatory guanine nucleotide binding protein (GSÎ±QL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene, 1999, 18, 3376-3382.	2.6	41
130	Calcitonin Inhibits Anterior Pituitary Cell Proliferation in the Adult Female Rats1. Endocrinology, 1999, 140, 4281-4291.	1.4	19
131	Emerging Drug Therapies for Mesothelioma. , 0, , .		1